恒瑞医药10款新药首次纳入2025医保目录

Core Viewpoint - Heng Rui Medicine has successfully included 10 new products in the 2025 National Medical Insurance Drug List, marking a significant milestone for the company in expanding its market presence in various therapeutic areas [1] Group 1: New Drug Inclusion - Heng Rui Medicine's 10 products cover multiple fields including oncology, metabolism, cardiovascular diseases, immune system diseases, and ophthalmology [1] - The specific drugs included are: - Injection of Rukang Qutuzumab - Sulfate of Amaglimin Tablets - Injection of Funachizumab - Injection of Rikasimab - Injection of Phosphororapitan Palonosetron - Regaglitin Metformin Tablets (I)/(II) - Famitin Acid Capsules - Acetate of Abiraterone Tablets (II) - Lipid Injection of Irinotecan Hydrochloride (II) - Perfluorohexyl Octane Eye Drops [1]